Cargando…

Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis

Background and Aims: Aspirin leads to substantial benefits for the secondary prevention of cardiovascular disease (CVD). We aimed to cast more light on aspirin’s role for the primary prevention of CVD. Methods: Databases were searched for clinical trials comparing aspirin vs. no aspirin use in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Binghao, Wu, Qian, Wang, Li, Liao, Chen, Dong, Yifei, Xu, Jingsong, Wei, Yiping, Zhang, Wenxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845480/
https://www.ncbi.nlm.nih.gov/pubmed/33519452
http://dx.doi.org/10.3389/fphar.2020.592116
_version_ 1783644559347023872
author Zhao, Binghao
Wu, Qian
Wang, Li
Liao, Chen
Dong, Yifei
Xu, Jingsong
Wei, Yiping
Zhang, Wenxiong
author_facet Zhao, Binghao
Wu, Qian
Wang, Li
Liao, Chen
Dong, Yifei
Xu, Jingsong
Wei, Yiping
Zhang, Wenxiong
author_sort Zhao, Binghao
collection PubMed
description Background and Aims: Aspirin leads to substantial benefits for the secondary prevention of cardiovascular disease (CVD). We aimed to cast more light on aspirin’s role for the primary prevention of CVD. Methods: Databases were searched for clinical trials comparing aspirin vs. no aspirin use in this meta-analysis. Efficacy and safety profiles were rigorously investigated. Trial sequential analysis (TSA) was used to determine the robustness of the results. Results: Fourteen studies with 163,840 participants were eligible (mean follow-up 6.2 y). Aspirin intake was found to be associated with 9, 13, and 12% reductions in the risk of cardiovascular events (CV events) (relative risk [RR]: 0.91, 95% confidence intervals [CI]: 0.87–0.96; risk difference (RD): 0.29%; absolute risk percentage (AR%): 7.61%; number needed to treat (NNT): 345), myocardial infarction (RR: 0.87, 95% CI: 0.77–0.97; RD: 0.21%; AR%: 11.11%; NNT: 488) and ischemic stroke (RR: 0.88, 95% CI: 0.80–0.96; RD: 0.21%; AR%: 16.14%; NNT: 476), respectively; aspirin intake was also associated with 40%, 30%, and 57% increases in the risk of major bleeding (RR: 1.40, 95% CI: 1.29–1.53; RD: 0.47%; AR%: 27.85; NNT: 214), intracranial bleeding (RR: 1.30, 95% CI: 1.11–1.52; RD: 0.10%; AR%: 22.99%; NNT: 1,000) and major gastrointestinal bleeding (RR: 1.57, 95% CI: 1.38–1.78; RD: 0.32%; AR%: 36.70%; NNT: 315), respectively. Further, populations with low doses of aspirin intake (≤100 mg), populations <65 y old or populations with body mass index (BMI) ≧ 25 experienced more advantages; high-risk (10-y cardiovascular risk ≧10%) and full diabetic individuals reported hardly clinical benefits. Conclusion: Aspirin intake was associated with a reduced risk of CV events and an increased incidence of bleeding profiles in primary prevention. It is necessary to identify individual’s CVD risk using clear examinations or assessments before aspirin intake, and truly realize individualized prescription.
format Online
Article
Text
id pubmed-7845480
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78454802021-01-30 Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis Zhao, Binghao Wu, Qian Wang, Li Liao, Chen Dong, Yifei Xu, Jingsong Wei, Yiping Zhang, Wenxiong Front Pharmacol Pharmacology Background and Aims: Aspirin leads to substantial benefits for the secondary prevention of cardiovascular disease (CVD). We aimed to cast more light on aspirin’s role for the primary prevention of CVD. Methods: Databases were searched for clinical trials comparing aspirin vs. no aspirin use in this meta-analysis. Efficacy and safety profiles were rigorously investigated. Trial sequential analysis (TSA) was used to determine the robustness of the results. Results: Fourteen studies with 163,840 participants were eligible (mean follow-up 6.2 y). Aspirin intake was found to be associated with 9, 13, and 12% reductions in the risk of cardiovascular events (CV events) (relative risk [RR]: 0.91, 95% confidence intervals [CI]: 0.87–0.96; risk difference (RD): 0.29%; absolute risk percentage (AR%): 7.61%; number needed to treat (NNT): 345), myocardial infarction (RR: 0.87, 95% CI: 0.77–0.97; RD: 0.21%; AR%: 11.11%; NNT: 488) and ischemic stroke (RR: 0.88, 95% CI: 0.80–0.96; RD: 0.21%; AR%: 16.14%; NNT: 476), respectively; aspirin intake was also associated with 40%, 30%, and 57% increases in the risk of major bleeding (RR: 1.40, 95% CI: 1.29–1.53; RD: 0.47%; AR%: 27.85; NNT: 214), intracranial bleeding (RR: 1.30, 95% CI: 1.11–1.52; RD: 0.10%; AR%: 22.99%; NNT: 1,000) and major gastrointestinal bleeding (RR: 1.57, 95% CI: 1.38–1.78; RD: 0.32%; AR%: 36.70%; NNT: 315), respectively. Further, populations with low doses of aspirin intake (≤100 mg), populations <65 y old or populations with body mass index (BMI) ≧ 25 experienced more advantages; high-risk (10-y cardiovascular risk ≧10%) and full diabetic individuals reported hardly clinical benefits. Conclusion: Aspirin intake was associated with a reduced risk of CV events and an increased incidence of bleeding profiles in primary prevention. It is necessary to identify individual’s CVD risk using clear examinations or assessments before aspirin intake, and truly realize individualized prescription. Frontiers Media S.A. 2021-01-14 /pmc/articles/PMC7845480/ /pubmed/33519452 http://dx.doi.org/10.3389/fphar.2020.592116 Text en Copyright © 2021 Zhao, Wu, Wang, Liao, Dong, Xu, Wei and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhao, Binghao
Wu, Qian
Wang, Li
Liao, Chen
Dong, Yifei
Xu, Jingsong
Wei, Yiping
Zhang, Wenxiong
Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
title Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
title_full Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
title_fullStr Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
title_full_unstemmed Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
title_short Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
title_sort pros and cons of aspirin for the primary prevention of cardiovascular events: a secondary study of trial sequential analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845480/
https://www.ncbi.nlm.nih.gov/pubmed/33519452
http://dx.doi.org/10.3389/fphar.2020.592116
work_keys_str_mv AT zhaobinghao prosandconsofaspirinfortheprimarypreventionofcardiovasculareventsasecondarystudyoftrialsequentialanalysis
AT wuqian prosandconsofaspirinfortheprimarypreventionofcardiovasculareventsasecondarystudyoftrialsequentialanalysis
AT wangli prosandconsofaspirinfortheprimarypreventionofcardiovasculareventsasecondarystudyoftrialsequentialanalysis
AT liaochen prosandconsofaspirinfortheprimarypreventionofcardiovasculareventsasecondarystudyoftrialsequentialanalysis
AT dongyifei prosandconsofaspirinfortheprimarypreventionofcardiovasculareventsasecondarystudyoftrialsequentialanalysis
AT xujingsong prosandconsofaspirinfortheprimarypreventionofcardiovasculareventsasecondarystudyoftrialsequentialanalysis
AT weiyiping prosandconsofaspirinfortheprimarypreventionofcardiovasculareventsasecondarystudyoftrialsequentialanalysis
AT zhangwenxiong prosandconsofaspirinfortheprimarypreventionofcardiovasculareventsasecondarystudyoftrialsequentialanalysis